Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Reloxin marketing narrows
Scottsdale, Ariz. - Ipsen and Medicis have announced they will not pursue an agreement to commercialize Ipsen's Reloxin (botulinum toxin type A) outside the United States, Canada and Japan.
Scottsdale, Ariz. - Ipsen and Medicis have announced they will not pursue an agreement to commercialize Ipsen's Reloxin (botulinum toxin type A) outside the United States, Canada and Japan.
Medicis was unable to structure a European distribution network on mutually acceptable economic terms because of official pricing and reimbursement policies in Europe, the company said.
Reloxin, known as Dysport in Europe, is in phase 3 trials in the United States for treatment of glabellar lines. Medicis aims to file for Food and Drug Administration approval in 2007.
Related Videos
Related Content
